Clinical Trial Update: Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating how Ledipasvir/Sofosbuvir affects the pharmacokinetics and renal safety of Tenofovir Alafenamide in patients with hepatitis C and HIV c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)
• Tenofovir alafenamide (TAF) (Tenofovir alafenamide)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Hepatitis C, HIV Coinfection | Phase 4 | Status: COMPLETED | Results posted: 2021-02-11